Medicare Enrolled

Dr. Amit Mehta, M.D.

Hematology & Oncology · Cary, NC
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
550 NEW WAVERLY PLACE SUITE 120, Cary, NC 27518
9193512260
In practice since 2007 (18 years)
NPI: 1740460377 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mehta from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mehta? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mehta

Dr. Amit Mehta is a hematology & oncology specialist in Cary, NC, with 18 years of NPI registration. Based on federal Medicare data, Dr. Mehta performed 27 Medicare services across 18 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mehta received a total of $3,847,209 from 58 pharmaceutical and/or device companies across 4790 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mehta is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ 27 Medicare services $3,847,209 industry payments

Medicare Practice Summary

Medicare Utilization ↗
27
Medicare services
Bottom 3% in NC for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
18
Unique beneficiaries
$89
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
 27 $89 $250
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$3,847,209
Total received (2018-2024)
Avg $549,601/year across 7 years
Top 0% in NC for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
58
Companies
4,790
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,512,208 (91.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$332,504 (8.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,497 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$611,781
2023
$704,945
2022
$725,877
2021
$522,672
2020
$349,389
2019
$563,028
2018
$369,517

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
EMD Serono, Inc.
$124,637
Astellas Pharma US Inc
$73,528
Janssen Biotech, Inc.
$69,317
PFIZER INC.
$64,339
Incyte Corporation
$49,300
Merck Sharp & Dohme LLC
$47,852
Pharming Healthcare, Inc.
$40,875
Aveo Pharmaceuticals, Inc.
$37,279
GENZYME CORPORATION
$34,963
PharmaEssentia USA Corporation
$18,349
Rigel Pharmaceuticals, Inc.
$17,159
Ipsen Biopharmaceuticals, Inc
$10,501
Sumitomo Pharma America, Inc.
$7,798
Pharmacosmos Therapeutics Inc.
$7,257
Geron Corporation
$5,336
Novartis Pharmaceuticals Corporation
$2,423
Medical Device Business Services, Inc.
$458
RECORDATI_RARE_DISEASES_INC.
$124
Exelixis Inc.
$69
Adaptive Biotechnologies Corporation
$66
E.R. Squibb & Sons, L.L.C.
$53
Amgen Inc.
$27
Bayer Healthcare Pharmaceuticals Inc.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$18
GlaxoSmithKline, LLC.
$16
Apellis Pharmaceuticals, Inc.
$14
Top 3 companies account for 43.7% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$590,314
Astellas Pharma US Inc
$469,935
EMD Serono, Inc.
$468,062
Incyte Corporation
$435,142
Rigel Pharmaceuticals, Inc.
$352,570
AMAG Pharmaceuticals, Inc.
$232,864
Janssen Biotech, Inc.
$207,987
Merck Sharp & Dohme LLC
$176,677
PharmaEssentia USA Corporation
$176,243
E.R. Squibb & Sons, L.L.C.
$160,305
GENZYME CORPORATION
$119,640
Aveo Pharmaceuticals, Inc.
$80,678
Pharming Healthcare, Inc.
$78,285
AVEO Pharmaceuticals, Inc.
$74,302
Pharmacosmos Therapeutics Inc.
$63,428
ADC Therapeutics America, Inc.
$49,435
Ipsen Biopharmaceuticals, Inc
$32,412
EUSA Pharma (US) LLC
$13,972
Pfizer Inc.
$8,404
Gilead Sciences, Inc.
$8,131
Sumitomo Pharma America, Inc.
$7,798
Merck Sharp & Dohme Corporation
$7,529
Seagen Inc.
$7,255
Geron Corporation
$5,336
Janssen Scientific Affairs, LLC
$4,552
Seattle Genetics, Inc.
$4,492
MorphoSys, US Inc.
$3,091
Novartis Pharmaceuticals Corporation
$2,505
Celgene Corporation
$1,820
Epizyme, Inc.,
$954
Bayer HealthCare Pharmaceuticals Inc.
$922
Medical Device Business Services, Inc.
$458
Adaptive Biotechnologies Corporation
$287
Takeda Pharmaceuticals U.S.A., Inc.
$229
Exelixis Inc.
$182
RECORDATI_RARE_DISEASES_INC.
$124
Daiichi Sankyo Inc.
$110
SANOFI-AVENTIS U.S. LLC
$85
Janssen Products, LP
$79
GlaxoSmithKline, LLC.
$55
Dova Pharmaceuticals
$53
AstraZeneca Pharmaceuticals LP
$51
CTI BioPharma Corp.
$50
Eisai Inc.
$50
Kyowa Kirin, Inc.
$47
Amgen Inc.
$41
Lexicon Pharmaceuticals, Inc.
$35
Janssen Pharmaceuticals, Inc
$32
Epizyme, Inc.
$31
Novo Nordisk Inc
$28
Olympus America Inc.
$26
Myovant Sciences Inc.
$24
Bayer Healthcare Pharmaceuticals Inc.
$23
Puma Biotechnology, Inc.
$15
Deciphera Pharmaceuticals Inc.
$14
Corcept Therapeutics
$14
Apellis Pharmaceuticals, Inc.
$14
Genentech USA, Inc.
$14
Top 3 companies account for 39.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AIHA · Abraxane · BAVENCIO · BESREMI · BLENREP · Bavencio · CABLIVI · CABOMETYX · CAMZYOS · Cabometyx · DARZALEX · Digital Flexible Ureteroscopes · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Empaveli · Enhertu · Erleada · FARESTON · FERAHEME · FOTIVDA · Fabhalta · HYQVIA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · IQIRVO · JADENU · JAKAFI · JEMPERLI · JEVTANA · JOENJA · KEYTRUDA · KISQALI · Korlym · Kyprolis · LUMAKRAS · LYNPARZA · Lenvima · MONJUVI · MONOFERRIC · Monoferric · Morphabond ER · NINLARO · Nerlynx · Nubeqa · OPDIVO · ORGOVYX · PADCEV · PLUVICTO · POTELIGEO · PROMACTA · Padcev · Pomalyst · QINLOCK · REBLOZYL · RUCONEST · RYTELO · Revlimid · Rezlidhia · SARCLISA · SPRYCEL · SUTENT · SYLVANT · Saxenda · ShockPulse - SE · Stivarga · Sylvant · TAGRISSO · TALZENNA · TAXOTERE · TAZVERIK · TRUFILL · TUKYSA · Tavalisse · Tazverik · Trodelvy · VELCADE · VENCLEXTA · VYNDAQEL · Vonjo · WELIREG · XARELTO · XTANDI · Xermelo · Xofigo · Xtandi · ZEJULA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (91%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in NC.

Looking for a hematology & oncology specialist in Cary?
Compare hematology & oncology specialists in the Cary area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
86
Per 100K population
7.5
County median income
$101,763
Nearest hospital
WAKEMED, CARY HOSPITAL
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Mehta is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 0% of NC peers, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Mehta experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Mehta performed 27 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mehta receive payments from pharmaceutical companies?
Yes. Dr. Mehta received a total of $3,847,209 from 58 companies across 4,790 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mehta's costs compare to other hematology & oncology specialists in Cary?
Dr. Mehta's average Medicare payment per service is $89. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mehta) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Hematology & Oncology Specialists in Cary
Browse hematology & oncology specialists in Cary ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NC
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NC
Which NC hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →